Liposomal prodrugs comprising derivatives of camptothecin...

Details Liposomal prodrugs comprising derivatives of camptothecin... Liposomal prodrugs comprising derivatives of camptothecin...

2000-02-08

2002-03-05

Lambkin, Deborah C. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S048000

Reexamination Certificate

active

06352996

ABSTRACT:

FIELD OF THE INVENTION
The present invention is directed to derivatives of camptothecin and is also directed to compositions including derivatives of camptothecin in delivery systems, preferably having low toxicity. The present invention also relates to the use of these derivatives for cancer treatment. The disclosures of all documents referred to in this application are incorporated herein in whole by reference.
BACKGROUND OF THE INVENTION
Camptothecin, a cytotoxic alkaloid first isolated from the wood and bark of
Camptotheca Acuminata
(Nyssaceae) by Wall and his coworkers (
J. Am. Chem. Soc
. 88, 3888, 1966), was shown to have antitumor activity against the mouse leukemia L 1210 system. The structure of camptothecin, an alkaloid which has a commonly occurring indole alkaloid group (Heckendorf et al,
J Org. Chem
. 41, 2045, 1976), is shown below as Formula (X).
This compound has a pentacyclic ring system with only one asymetrical center in ring E with a 20(S)-configuration. The pentacyclic ring system includes a pyrrolo [3, 4-b] quinoline moiety (rings A, B and C), a conjugated pyridone (ring D), and a six-membered lactone (ring E) with an &agr;-hydroxyl group. Camptothecin was of great interest from the time of its initial isolation due to its noteworthy activity in the mouse leukemia L 1210 system. Earlier data for the antitumor activity of camptothecin were obtained by employing experimentally transplanted malignancies such as leukemia L1210 in mice, or Walker 256 tumor in rats (
Chem. Rev
. 23, 385, 1973
, Cancer. Treat. Rep
. 60, 1007, 1967). Subsequent clinical studies showed that this compound was not usable as an anticancer agent in vivo due to its high toxicity. Camptothecin itself is insoluble in water. Therefore, camptothecin was evaluated clinically as a water-soluble sodium carboxylate salt in the early times. This form of camptothecin produced severe toxicity and seemed devoid of anticancer activity (Gottlieb et al,
Cancer Chemother. Rep
. 54, 461, 1970, and 56, 103, 1972, Muggia et al,
Cancer Chemother. Rep
. 56, 515, 1972, Moertel et al,
Cancer Chemother. Rep
. 56, 95, 1972, and Schaeppi et al,
Cancer Chemother. Rep
. 5:25, 1974). These results caused the discontinuation of phase II trials. Continued evaluation of this agent showed that the sodium carboxylate salt is only 10% as potent as the native camptothecin with the closed lactone ring intact (Wall et al,
In International Symposium on Biochemistry And Physiology of The Alkaloids, Mothes et al, eds, Academie—Verlag, Berlin
, 77, 1969, Giovanella et al,
Cancer res
. 51, 3052, 1991). In addition, important parameters for antitumor activity in the camptothecin family have been established (Wall et al,
Ann. Rev., Pharmacol. Toxicol
. 17, 117, 1977). These results indicate that intact lactone ring E and &agr;-hydroxyl group are essential for antitumor activity.
In 1989, Giovanella et al. found that some of the non-water soluble derivatives of camptothecin have high antitumor activity against xenograft of human tumors (Giovanella et al.,
Science
, 246, 1046, 1989). It has also been shown that administration of camptothecin with closed lactone ring is superior to injections of water-soluble carboxylate salt (Giovanella et al,
Cancer Res
., 51, 3052, 1991). These findings further confirmed the importance of the intact lactone ring.
Clearly, there is a need to modify 20(S)-camptothecin (“CPT”) to enable the lactone form to stay longer in the body while retaining the structural elements (i.e. 20-hydroxyl and lactone ring E) which are essential for its antitumor activity.
Ring opening of CPT leads to much more potent anticancer activity in mice than in humans. In effect, CPT administered intramuscularly (“i.m.”), subcutaneously (“s.c.”), and intrastomach (“i.s.”) has proved to be a very potent anticancer agent against human tumors in mice, i.e., when growing as xenotransplants in nude mice (Giovanella et al,
Cancer Res
. 51:3052, 1991). However, when tumors were treated with CPT in humans, a lower degree of anticancer activity in humans, than in mice, was exhibited (Stehlin et al., In Camptothecins: New Anticancer Agents, 1995, CRC Press, pp. 59-65).
The same phenomenon was observed with other CPT-derivatives. In mice, 9-nitrocamptothecin (“9NC”) has proven to be 2-3 times more potent than CPT against human tumor xenografts causing the total eradication of all the human malignancies treated (Pantazis et al., Cancer Res. 53:1577, 1993; Pantazis et al., Int. J. Cancer 53:863, 1995).
Pharmacological studies demonstrated that the majority (57%) of the 9NC drug present in the plasma after i.s. administration is in the closed lactone form (FIG.
3
). Pharmacological studies on the plasma levels of 9NC after oral administration to Phase I clinical trial patients demonstrate that, on average, only ~3% of the drug present is in the closed lactone form (FIGS.
4
and
5
).
In perfect agreement with such findings, the clinical responses in this group of patients, although higher than those obtained with CPT are still a far cry below the results obtained in mice (32/32 complete tumor regressions in mice versus 2/32 in humans). Clearly, again there is a pressing need for a modification which will slow and delay the lactone ring opening upon its entrance into the blood circulation.
A number of attempts have been made to provide more active derivatives of camptothecin and longer lasting forms. U.S. patent application Ser. No. 09/030,357 to Cao et al. provides CPT-derivatives which are effective antitumor agents. In addition, Cao et al. describe in the application new active CPT-derivatives which sustain the opening of the lactone ring E, which makes the antitumor activity last longer than its mother analog, CPT. Unfortunately, because a mammalian body breaks down CPT-derivatives over time by opening the lactone ring, a need still exists for a CPT-derivative delivery system that keeps the CPT-derivative intact even longer in the body, thus prolonging the antitumor activity of the derivative.
SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide a new liposomal delivery system for CPT-derivatives which enables the derivatives to remain intact longer in a mammalian body, particularly in a human body.
It is another object of the present invention to provide a new liposomal delivery system for water insoluble CPT-derivatives possessing good absorbability in the living body.
It is still another object of the present invention to provide a new liposomal delivery system for CPT-derivatives which retains the lactone ring E and the 20-hydroxyl group intact, which is important for antitumor activity.
It is still a further object of the present invention to provide a method for preparing CPT-derivatives, preferably water insoluble derivatives, in a liposomal delivery system.
Additional objects and advantages of the present invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. The objects and advantages of the present invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
To achieve the objects and in accordance with the purpose of the present invention, as embodied and broadly described herein, the present invention relates to a compound of the formula:
wherein R
2
is H, NH
2
, or NO
2
and R
1
is a C
2
-C
4
alkyl group, a C
6
-C
15
alkyl group, a C
3
-C
8
cycloalkyl group, a C
2
-C
15
alkenyl group, or an epoxy group when R
2
is H; and R
1
is a C
1
-C
15
alkyl group, a C
1
-C
15
alkenyl group, a C
3
-C
8
cycloalkyl group, or an epoxy group when R
2
is NO
2
.
The invention also relates to a method for treating cancer and/or malignant tumors in a mammal and comprises administering an effective amount of one or more of the above CPT-derivatives in a liposomal delivery system.


REFERENCES:
patent: 3894029 (1975-07-01), Winterfeldt et al.
patent: 4399282 (1983-08-01), Miyasaka e

Affiliated with

Also associated with

Rating

Liposomal prodrugs comprising derivatives of camptothecin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomal prodrugs comprising derivatives of camptothecin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal prodrugs comprising derivatives of camptothecin... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2857914